In pancreatic cancer, overexpression of miRNA-125a, miRNA-320c, and miRNA-1246 suppressed the activity of cyclin G2 (CCNG2), SMARCC1 (chromatin subfamily C member 1), and A20 (a zinc finger family protein), resulting in reduced drug sensitivity [97]. This evidence concerns the gene CCNG2 and pancreatic neoplasm.